Key Highlights
-
The price of erythromycin, a key precursor for clarithromycin, has been volatile, impacting overall production costs.
-
New pricing regulations from the National Pharmaceutical Pricing Authority (NPPA) in India have indirectly influenced clarithromycin&#xx;s pricing structure.
-
Chinese stockpile depletion and port congestion have exacerbated supply issues, leading to inflated prices.
-
Anticipation of tariff hikes has prompted significant pre-emptive buying, further driving up demand and prices.
The prices of clarithromycin have been heavily influenced by seasonal fluctuations and international health trends. The prices of clarithromycin (FOB Shanghai) in August stood at USD xxx,xxx/MT, which remained a consistent rise compared to USD xxx,xxx/MT in July. Respiratory disorders in different countries, especially in China, increased, thereby increasing the demand for clarithromycin. Further, collusive stockpiling by large buyers in ASEAN and Latin America has stripped Chinese inventories bare, leading to supply gaps. Retail pharmacy sales are also increasing as rural market health programs push up...
